Home/Blogs/Blog details

Novel Drug Promises To Increase Life Expectancy In The Treatment Of Mesothelioma

Mar 27, 2017

Novel Drug Promises To Increase Life Expectancy In The Treatment Of Mesothelioma

The malignant mesothelioma is one of the rare and most aggressive cancers in nature. It develops mainly in the lining of the lungs, i.e., pleural mesothelioma or the abdomen, i.e., peritoneal mesothelioma. This cancer accounts for almost 90 percent of all the malignant mesothelioma cases.It is mainly caused due to inhaling asbestos which is a fiber that is usually and widely found vinyl floor tiles, some forms of insulation, and several other materials. The cancerous tumor form in the pleura, which is a thin membrane of cells lining the chest and the lungs walls. Most patients suffering from mesothelioma survive less than a year, and this pitiable prognosis is owing to the fact that most of the patients are already at the last stage opf this cancer when being diagnosed. Drug Details Pembrolizumab is an antibody drug which has already been in use for treating several other types of cancer. This drug can also be effectively use to treat the most common form of mesothelioma, says a new study. The newly published research study is the first to demonstrate a positive impact from the checkpoint inhibitor immunotherapy drugs on mesothelioma. The standard initial therapy treatment includes chemotherapy, and presently there is no approved second therapy. Earlier there have been several studies considering many drugs, however researchers did not notice any positive results.The new study has determined new class of drugs, checkpoint inhibitors, appears to be more efficient than the drugs available in the past. Checkpoint inhibitors are a specifically designed class of drugs fabricated to set the immune system of the body free to combat cancer. Pembrolizumab, especially has been used for the treatment of non-small cell lung cancer, melanoma and in certain cases neckand head cancers. A current trial which includes 13 different research sites in six countries across the world, all of whom are evaluating the effects of pembrolizumab on cancer patients who have extreme malignancies. The established study assessed 25 patients with pleural mesothelioma. The patients were above 18 years of age and had either not abloe to receive chemotherapy or had earlier been treated with chemotherapy. Starting with the initial set of people two years ago, the doctors administered each patient a dosage of pembrolizumab once every two weeks. This showed that the tumor had reduced in 14 of the patients. Most of the patients who got second-line therapy received a life expectancy of nearly six to seven months. The most common side-effects of the drug recorded was nausea, dry mouth, fatigue and loss of appetite.

footer pattern

All Copyrights reserve worldhealthcarenews.biz 2017.